HC Wainwright Estimates MannKind's Q1 Earnings (NASDAQ:MNKD)

Key Points

• HC Wainwright lowered its Q1 2026 EPS estimate for MannKind to ($0.06) from ($0.03) but maintained a Buy rating and an $11.00 price target, while projecting FY2026 EPS of ($0.19) and FY2028 EPS of ($0.09).
• MannKind reported ($0.05) EPS in its most recent quarter—missing consensus by $0.04—while revenue rose 45.8% year-over-year to $111.96 million.
• Analyst sentiment is mixed with several firms trimming price targets (consensus “Moderate Buy” and $8.56 average target), and insider activity notable as CEO Michael Castagna bought 100,000 shares at $2.59, leaving insiders with about 2.6% ownership.

MannKind Corporation (NASDAQ:MNKD - Free Report) - HC Wainwright lowered their Q1 2026 earnings per share estimates for MannKind in a research note issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.03). HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for MannKind's current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for MannKind's Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.19) EPS and FY2028 earnings at ($0.09) EPS.

MannKind (NASDAQ:MNKD - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The business had revenue of $111.96 million during the quarter, compared to analysts' expectations of $99.85 million. MannKind had a negative return on equity of 11.21% and a net margin of 1.68%.The company's revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.03 earnings per share.

MNKD has been the topic of a number of other reports. Mizuho decreased their price target on MannKind from $10.00 to $8.00 and set an "outperform" rating on the stock in a research note on Monday, April 13th. Wedbush decreased their price target on MannKind from $10.00 to $8.00 and set an "outperform" rating on the stock in a research note on Thursday, March 5th. Wall Street Zen cut MannKind from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Wells Fargo & Company decreased their price target on MannKind from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Friday, February 27th. Finally, Zacks Research upgraded MannKind from a "strong sell" rating to a "hold" rating in a research note on Wednesday, April 15th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $8.56.

MannKind Stock Performance

Shares of MannKind stock opened at $2.70 on Monday. The firm has a market capitalization of $833.76 million, a price-to-earnings ratio of 135.07 and a beta of 1.04. MannKind has a fifty-two week low of $2.23 and a fifty-two week high of $6.51. The stock has a 50 day moving average of $3.09 and a 200 day moving average of $4.70.

Insider Activity

In related news, CEO Michael Castagna acquired 100,000 shares of MannKind stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $2.59 per share, for a total transaction of $259,000.00. Following the completion of the purchase, the chief executive officer owned 2,575,911 shares in the company, valued at approximately $6,671,609.49. The trade was a 4.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.60% of the company's stock.

Institutional Trading of MannKind

Several hedge funds have recently modified their holdings of MNKD. AQR Capital Management LLC raised its stake in shares of MannKind by 19.8% in the first quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company's stock valued at $278,000 after acquiring an additional 9,160 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of MannKind by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company's stock valued at $1,059,000 after acquiring an additional 6,079 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of MannKind by 8.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company's stock valued at $3,374,000 after acquiring an additional 53,202 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of MannKind by 42.7% in the second quarter. JPMorgan Chase & Co. now owns 1,352,017 shares of the biopharmaceutical company's stock valued at $5,057,000 after acquiring an additional 404,842 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of MannKind by 84.8% in the second quarter. Prudential Financial Inc. now owns 37,381 shares of the biopharmaceutical company's stock valued at $140,000 after acquiring an additional 17,150 shares in the last quarter. 49.55% of the stock is currently owned by institutional investors and hedge funds.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company's core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind's lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.